RESUMEN
BACKGROUND: The aim of this study was to explore the association of immune and liver functions' alteration in mycoplasma pneumoniae pneumonia (MPP) children with the therapeutic effect of andrographolide sulfonate's curative outcome. METHODS: From January 2019 to April 2021, a group of 102 MPP child patients was divided into severe and mild cases in the light of the disease's severity, and involvement of 57 healthy child patients during the identical period was as the control. Comparison of immune function among three groups [immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM)] and liver function indexes [Alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transferase (GGT)] was to analyze its association and assessment value for the illness's severity. RESULTS: IgA and IgM in MPP child patients were declined with the illness's severity, while ALT, AST and GGT were elevated with it (p < 0.05). AUC of combined detection of immune and liver function indexes in assessing MPP's severity in children was augmented vs. each index's alone examination (p < 0.05). IgA was negatively associated with MPP's severity in children, while ALT, AST, and GGT were positively associated with it (p < 0.05). IgA in the effective was augmented vs. the noneffective, while ALT, AST, and GGT were declined vs. the noneffective (p < 0.05). CONCLUSIONS: The immune and liver functions of MPP child patients are associated with the illness's severity and provide an assessment value for the disease's severity and Andro-S's curative outcome.
Asunto(s)
Mycoplasma pneumoniae , Neumonía por Mycoplasma , Humanos , Niño , Neumonía por Mycoplasma/diagnóstico , Neumonía por Mycoplasma/tratamiento farmacológico , gamma-Glutamiltransferasa , Alanina Transaminasa , Hígado , Inmunoglobulina A , Inmunoglobulina MRESUMEN
BACKGROUND: To figure out the effect of andrographolide sulfonate on the clinical efficacy and immune function of children with mycoplasma pneumoniae pneumonia (MPP). METHODS: From January 2019 to April 2021, a total of 102 children with MPP were selected as the research group. They were assigned into the control and the observation groups by random number table method, with 51 cases/group. The control group was given routine treatment, and the observation was given andrographolide sulfonate treatment. The therapeutic efficacy and improvement of clinical symptoms were compared between the two. The changes of immune function, pulmonary function, myocardial enzymology indexes, MCP-4, IL-1ß, IFN-γ, and TNF-α were noticed in the groups before and after treatment. The presence of drug-related adverse reactions of patients was recorded during treatment. RESULTS: The total effective rate of treatment in the observation group was higher, and the time of fever reduction, pulmonary rales disappearance and cough disappearance time were all shorter vs. the control group (p < 0.05). Immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) in the observation group after treatment were higher, and monocyte chemoattractant protein 4 (MCP-4), interleukin-1ß (IL-1ß), interferon-γ (IFN- γ), and tumor necrosis factor-α (TNF-α) were reduced vs. the control group. The forced expiratory volume in the 1st second (FEV1) and the percentage of forced vital capacity occupied by the forced expiratory volume in the first second (FEV1/FVC) and peak expiratory flow (PEF) values were higher (p < 0.05), but aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and creatine kinase (CK) and isoenzyme (CK-MB) were reduced in the observation group after treatment vs. the control group (p < 0.05); No serious adverse reactions took place in the two during treatment. CONCLUSIONS: The treatment of andrographolide sulfonate in children with MPP can enhance the therapeutic effect, ameliorate the immune function and lung function of children, and reduce inflammation and myocardial enzymes.